Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- Cylinder Health strengthens gut-brain leadership with new Head of Gut-Brain Health and Clinical Advisory Board appointment (Cylinder Health)
- The new era of physician independence (Medical Economics)
- “Don’t Take Shortcuts,” Endoscopy Researcher Advises (GI & Hepatology News)
- Olympus Unveils Corporate Strategy (Olympus)
- Unlocking value creation in healthcare: How AI can reverse private equity’s return challenges – Part 1: HealthTech and tech-enabled services (Lexology)
- 5 highest-paid gastroenterologists in New York City (Becker’s GI & Endoscopy)
- And Your 2025 Healio Disruptive Innovators Are … (Healio)
- The Hype and Limits of At-Home Gut Microbiome Tests (U.S. News)
